Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have earned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $41.00.

A number of equities research analysts recently issued reports on ELVN shares. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $16.86 on Monday. The business’s fifty day moving average price is $20.79 and its two-hundred day moving average price is $20.42. Enliven Therapeutics has a fifty-two week low of $13.30 and a fifty-two week high of $25.37. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of -9.16 and a beta of 0.35.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Research analysts expect that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Anish Patel sold 6,663 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $21.02, for a total transaction of $140,056.26. Following the sale, the chief operating officer owned 263,311 shares in the company, valued at approximately $5,534,797.22. This represents a 2.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samuel Kintz sold 12,500 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $21.82, for a total value of $272,750.00. Following the completion of the sale, the chief executive officer owned 890,392 shares of the company’s stock, valued at approximately $19,428,353.44. This trade represents a 1.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 98,247 shares of company stock valued at $2,043,650. Company insiders own 25.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quantbot Technologies LP acquired a new stake in Enliven Therapeutics in the 1st quarter valued at about $60,000. BNP Paribas Financial Markets increased its holdings in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. AlphaQuest LLC bought a new position in Enliven Therapeutics in the 3rd quarter worth approximately $96,000. Tower Research Capital LLC TRC lifted its holdings in Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after buying an additional 3,490 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its position in Enliven Therapeutics by 58.1% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after buying an additional 2,500 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.